Replies to post #5868 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff, Amag projected $365 million in sales for Makena for 2016. How much of this market ANI captures is anybody's guess.

No, it was not included in the last guidance as the guidance was provided prior to the deal with Aspen.

In the last conference call Pryzbyl mentioned the possibility of bundling products in sales. The price would be better for the client but ANI would gain bigger contracts with greater volumes and greater profits though at lower margins then they were presently running. I may be wrong here, but the need to start a second shift as opposed to increasing the existing shift may be an indication that they received some of those bundled contracts where they could not meet demand on one shift. If so, revenues should increase significantly by adding products and capturing greater market share of their existing product line.


JMHO